ARX
data caveat$224MCF+
Aroa Biosurgery
Medical Devices · Wound care
Myriad and Symphony extracellular matrix surgical products for tissue repair
Data HealthTrials1 of 2 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$27.0M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$224M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
347M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveAnnual Report25 May 2026
FY26 Full Year Results Presentation
Cash$27.0M·Burn$10.5M/q·OCF$10.5M
3M Price
ARX.ASX$0.645+7.5% 3M
Low $0.510High $0.695
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
1 noticearrow_drop_upAcorn Capital Limited
8.63%2026-05-27
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-05-28 · 4-day lag
Short position
0.03%
arrow_drop_down-0.11% over 30 reports
Shares short
0.1M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Catalysts (3)
Myriad US revenue growth update
OverdueConfirmedremoveMed30 Apr 2026
SpeculativeremoveMed1 Feb 2027
SpeculativeMed
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 2/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(4)
2 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1612d
Myriad Matrix™ and Myriad Morcells™
Myriad™ Augmented Soft Tissue Reconstruction Registry
Abdominal Wound Dehiscence · Necrotizing Soft Tissue Infection · Lower Extremity Wound +4 more
18 Years+
Primary endpoint Proportion of participants with treatment emergent adverse events during the study
ENROL800
no manual snapshots — enter via record_enrollment.py
Ph4Recruiting
Myriad™ applied in conjunction with NPWTNPWT Alone
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
Soft Tissue Defects · Soft Tissue Wounds · Traumatic Soft Tissue Defect
RandomizedOpen Label18 Years+
Primary endpoint Tissue Coverage
ENROL30
no manual snapshots — enter via record_enrollment.py
Announcements(14)
description
Annual Reportauto_awesome
FY26 Full Year Results Presentation - Correction26 May 2026
expand_more2397KB
description
Annual ReportPSauto_awesome
FY26 Full Year Results Presentation25 May 2026
expand_more2165KB
description
Half YearPSauto_awesome
FY26 Appendix 4E and Full Year Results25 May 2026
expand_more4523KB